Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Primary Central Nervous System Lymphoma

An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: ONO Pharmaceutical Co., Ltd.

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Primary Central Nervous System Lymphoma Clinical Trial

Schedule an Appointment